Montanide ISA 51 VG

Phase 2Small molecule

NNational Cancer Institute (NCI)

Montanide ISA 51 VG is one of 16 small molecule programs targeting Lung Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CarcinomaNot yet recruiting

Lung CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

16 competitors in Lung Carcinoma

#DrugCompanyPhaseTrials

Lumakras

Amgen

Approved

1 2

Afinitor

Iressa

Chantix

PPrism Pharmaceuticals

Approved

—5

Aurlumyn

BBTG International Inc.

Approved

—6

Navelbine

PPierre Fabre Medicament

Leukine

1 8

Vectibix

Amgen

Preclinical

1 9

Nicorette

Nicotine Replacement

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Glioblastoma

NCT02455557

Q4 2029

Phase 2Not yet recruiting

Lung Carcinoma

NCT07169617

Clinical

Trials by Indication[1]

Melanoma3 trials

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00089063·40 enrolled

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Completed·MMayo Clinic·Phase 1·NCT01748747·30 enrolled

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00085189·42 enrolled

Metastatic Melanoma2 trials

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00019682·185 enrolled

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00923195·4 enrolled

Immune Response1 trial

KLH Challenge to Explore the Human Immune Response

Unknown status·UUniversity of Oxford·N/A·NCT05876195·39 enrolled

Myelodysplastic Syndrome1 trial

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00004918·69 enrolled

Acute Myeloid Leukemia1 trial

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Completed·UUniversity of Chicago·Phase 1·NCT01842139·7 enrolled

3 more indications

Peptides1 trial

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01176461·127 enrolled

Glioblastoma1 trial

A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma

Active, not recruiting·RRoswell Park Cancer Institute·Phase 2·NCT02455557·66 enrolled

Lung Carcinoma1 trial

Evaluating the Feasibility of a Survivin Peptide Vaccine (SurVaxM) as an Interception Agent in Patients at High Risk for Lung Cancer

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07169617·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Montanide ISA 51 VG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Montanide ISA 51 VG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Montanide ISA 51 VG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Montanide ISA 51 VG

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2029

Trials by Indication[1]

Melanoma3 trials

Metastatic Melanoma2 trials

Immune Response1 trial

Myelodysplastic Syndrome1 trial

Acute Myeloid Leukemia1 trial

Peptides1 trial

Glioblastoma1 trial

Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News